Abstract.
The novel, selective dopamine D3 receptor antagonist, S33084 [(3aR,9bS)-N[4-(8-cyano-1,3a,4,9b-tetrahydro-3H-benzopyrano[3,4-c]pyrrole-2-yl)-butyl] (4-phenyl)benzamide], was tritium-labelled to 59 Ci/mmol specific activity. Determination of association and dissociation rate constants at recombinant, human (h) D3 receptors stably expressed in Chinese hamster ovary (CHO) cells yielded a K d value (0.16 nM) comparable to that observed in saturation binding experiments (0.17 nM). The competition binding profile of [3H]S33084 with diverse D3 receptor agonists and antagonists correlated highly (0.99) with that of [3H]spiperone. In conclusion, [3H]S33084 is a highly potent and selective radioligand at dopamine D3 receptors, which should be of considerable use for their characterisation.
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Cussac, D., Newman-Tancredi, A., Sezgin, L. et al. [3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors. Naunyn-Schmied Arch Pharmacol 361, 569–572 (2000). https://doi.org/10.1007/s002100000217
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002100000217